Skip to main content
SpringerLink
Log in

Reduction of Suicidality in Patients with Schizophrenia Receiving Clozapine

  • Short Communicaton
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Kane JM, Honigfeld G, Singer J, et al. Clozapine for treatmentresistant schizophrenia. Arch Gen Psychiatry 1988; 45: 789–96

    Article  PubMed  CAS  Google Scholar 

  2. Meltzer H, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990; 41: 892–7

    PubMed  CAS  Google Scholar 

  3. Pickar D, Owen RR, Litman RE, et al. Clinical and biological response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 1992; 49: 345–53

    Article  PubMed  CAS  Google Scholar 

  4. Breier A, Buchanan RW, Irish D, et al. Clozapine treatment of outpatients with schizophrenia: outcome and long-term response patterns. Hosp Community Psychiatry 1993; 22: 1145–9

    Google Scholar 

  5. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on postiive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994; 151: 20–6

    PubMed  CAS  Google Scholar 

  6. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and preditctors of outcome. Am J Psychiatry 1994; 151: 1744–52

    PubMed  CAS  Google Scholar 

  7. Rosenheck R, Cramer J, Xu W, et al. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. A comparison of clozapine and haloperidol in hospitalised patients with refractory schizophrenia. N Engl J Med 1997; 337: 809–15

    Article  PubMed  CAS  Google Scholar 

  8. Gelder M. Gath D, Mayou R, et al. (editors) Schizophrenia and schizophrenia-like disorders. In: Oxford Textbook of Psychiatry. 3rd ed. New York: Oxford University Press, 1996: 246–293

  9. Jablensky A. Epidemiology of schizophrenia: a European perspective. Schizophr Bull 1986; 12: 52–73

    Article  PubMed  CAS  Google Scholar 

  10. Hafner H, Riecher A, Maurer K, et al. How does gender influence age at first hospitalization of schizophrenia. Psychol Med 1989; 19: 903–18

    Article  PubMed  CAS  Google Scholar 

  11. Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr Serv 1998; 49(8): 1029–33

    PubMed  CAS  Google Scholar 

  12. Schuttler R, Huber G, Gross G. Suizid and Suizidversuch im Verlauf schizophrener Erkrankungen. Psychiatr Clin (Basel) 1976; 9: 97–105

    Google Scholar 

  13. Modestin J. Suizid in der psychiatrischen Klinik. Stuttgart: Enke, 1987

    Google Scholar 

  14. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152: 183–90

    PubMed  CAS  Google Scholar 

  15. Ehrlinger R. Evaluation of suicide prevention after attempted suicide. Acta Psychiatr Scand Suppl 1975; 260: 64–124

    Google Scholar 

  16. Kreitman N, editor. Parasuicide. New York: John Wiley & Sons, 1977

    Google Scholar 

  17. Westermeyer JF, Harrow M, Marengo JT. Risk for suicide in schizophrenia and other psychotic and non-psychotic disorders. J Nerv Ment Dis 1991; 179: 259–66 (as cited in Reid [4])

    Article  PubMed  CAS  Google Scholar 

  18. Caldwell CB, Gottesman II. Schizophrenics kill themselves too: Areview of risk factors for suicide. Schizophr Bull 1990; 16: 571–89 (as cited in Reid[4])

    Article  PubMed  CAS  Google Scholar 

  19. Sernyak MJ, Desi R, Stolar M, et al. Impact of clozapine on completed suicide. Am J Psychiatry 2001; 158: 931–7

    PubMed  CAS  Google Scholar 

  20. Ereschefsky L, Watanabe MD, Tran-Johnson TK. Clozapine: an typical antipsychotic agent. Clin Pharm 1989–8: 691–709

    Google Scholar 

  21. Lieberman JA, Alvir JMJ. A report of clozapine-induced agranulocytosis in the United States. Incidence and risk factors. Drug Saf 1992; 7: 1–2

    Article  PubMed  Google Scholar 

  22. Reinstein MJ, Sirotouskaya LA, Mohan SC, et al. Incidence and treatment of side effects with clozapine treatment [poster]. Presented at the Annual Meeting of the American Psychiatric Association, Chicago, 8 May 2000

  23. Marder SR, Van Putten T. Who should receive clozapine? Arch Gen Psychiatry 1988; 45: 865–7

    Article  PubMed  CAS  Google Scholar 

  24. Earle KA, Forquer SL, Volo AM, et al. Characteristics of outpatient suicides. Hosp Community Psychiatry 1994; 45: 123–6

    PubMed  CAS  Google Scholar 

  25. Meltzer HY. Suicide and schizophrenia: Clozapine and the InterSePT study. J Clin Psychiatry 1999; 60 Suppl. 2: 47–50

    CAS  Google Scholar 

  26. Taiminen TJ, Kujari H. Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients. Acta Psychiatr Scand 1994; 90: 247–51 (as cited in Meltzer[25])

    Article  PubMed  CAS  Google Scholar 

  27. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671–7 (as cited in Meltzer[25])

    PubMed  CAS  Google Scholar 

  28. Meltzer HY. Suicide in schizophrenia: Risk factors and clozapine treatment. J Clin Psychiatry 1988; 59 Suppl. 3: 15–20

    Google Scholar 

Download references

Acknowledgements

Funding support for this study was provided by Novartis Pharmaceuticals.

Author information

Authors and Affiliations

  1. Uptown Research Institute, LLC, 4755 N. Kenmore Avenue, Chicago, Illinois, 60640, USA

    Michael J. Reinstein, Maxim A. Chasonov, Kathleen D. Colombo, Lynne E. Jones &  John G. Sonnenberg

Authors
  1. Michael J. Reinstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maxim A. Chasonov
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kathleen D. Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lynne E. Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. John G. Sonnenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reinstein, M.J., Chasonov, M.A., Colombo, K.D. et al. Reduction of Suicidality in Patients with Schizophrenia Receiving Clozapine. Clin. Drug Investig. 22, 341–346 (2002). https://doi.org/10.2165/00044011-200222050-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200222050-00008

Keywords

Search

Navigation